Pharmacokinetic/pharmacodynamic modeling of the cardiovascular effects of beta blockers in humans

Archives of Pharmacal Research

Volumn 31, Issue 6, 2008, Pages 814-821

  Baek, In Hwan ^a   Yun, Min Hyuk ^b   Yun, Hwi Yeol ^a   Kwon, Kwang Il ^a  

^a Chungnam National University   (South Korea)

^b Samyang Corporation   (South Korea)

Author keywords

Atenolol; Biophase model; Carveilol; Diastolic blood pressure; Pharmacokinetic pharmacodynamic; Systolic blood pressure

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; CARVEDILOL; PROPANOLAMINE DERIVATIVE;

ADULT; ARTICLE; ASIAN; BIOLOGICAL MODEL; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KOREA; MALE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; ATENOLOL; BLOOD PRESSURE; CARBAZOLES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; KOREA; MALE; MODELS, CARDIOVASCULAR; PROPANOLAMINES;

EID: 45749110644     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-001-1231-4     Document Type: Article

References (19)

1. Bristow, M. R., Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am. J. Cardiol., 71, 12C-22C (1993).
2. Carlberg, B., Samuelsson, O., and Lindholm, L. H., Atenolol in hypertension: is it a wise choice? Lancet, 364, 1684-1689 (2004).
3. Carmo, Borges, N. C., Mendes, G. D., Diogo, de, Oliveira, Silva, D., Marcondes, Rezende, V., Barrientos-Astigarraga, R. E., and De, Nucci, G., Quantification of carvedilol in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry: application to bioequivalence study. J. Chromatoqr. B. Analyt. Technol. Biomed. Life Sci., 822, 253-262 (2005).
4. Deredort, H. and Meibohm, B., Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm. Res., 16, 176-185 (1999).
5. Dobson, C. L., Davis, S. S., Chauhan, S., Sparrow, R. A., and Wilding, I. R., The effect of ileal brake activators on the oral bioavailability of atenolol in man. Int. J. Pharml., 248, 61-70 (2002).
6. De, Abreu, L. R., De, Castro, S. A., and Pedrazzoli, J. J., Atenolol quantification in human plasma by high-performance liquid chromatography: application to bio-equivalence study. AAPS. PharmSci., 5, E 21 (2003).
7. Fitzqerald, J. D., Ruffin, R., Smedstad, K. G., Roberts, R., and McAinsh, J., Studies on the pharmacokinetics and pharmacodynamics of atenolol in man. Eur. J. Clin. Pharmacol., 13, 81-89 (1978).
8. Fraishman, W. H., Carvedilol. N. Engl. J. Med., 339, 1759-1765 (1998).
9. Ishizaki, T., Ohnishi, A., Sasaki, Y., Chiba, K., Suganuma, T., and Kushida, K., Concentration-effect and time-effect relationships of carteolol. Eur. J. Clin. Pharmacol., 25, 749-757 (1983).
10. Krukemyer, J. J., Use of beta-adrenergic blocking agents in congestive heart failure. Clin. Pharm., 9, 853-863 (1993).
11. Luizer, A. B., Killian, A., Wilton, J. H., Wilson, M. F., Forrest, A., and Kazierad, D. J., Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin. Pharmacol. Ther., 66, 594-601 (1999).
12. Lilija, J. J., Backman, J. T., and Neuvonen, P. J., Effect of itraconazole on the pharmacokinetics of atenolol. Basic Clin. Pharmacol. Toxicol., 97, 395-398 (2005).
13. Mirfazaelian, A., Tabatabaeifar, M., Rezaee, S., and Mahmoudian, M., Bioequivalence study of atenolol: pharmacokinetic and pharmacodynamic evaluation. Daru., 11, 1-4 (2003).
14. Perez-Urizar, J., Granados-Soto, V., Flores-Murrieta, F. J., and Castaneda-Hernandez, G., Pharmacokinetic-pharmacodynamic modeling: why? Arch. Med. Res., 31, 539-545 (2000).
15. Shargel, L. and Yu, A. B. C., Applied biopharmaceutics and pharmacokinetics; 4th Edt. Appleton and Lange, Norwalk, Connecticut, pp. 573-606, (1999).
16. Tabacova, S. and Kimmel, C., Atenolol: pharmacokinetic/dynamic aspects of comparative developmental toxicity. Reprod. Toxicol., 16, 1-7 (2001).
17. Tereno, D. M., Henderson, L. S., Campanile, A. M., Baidoo, C. A., and Bovle, D., Development of a pharmacokinetic/pharmacodynamic model for carvedilol to predict beta1-blockade in patients with congestive heart failure. Am. J. Cardiol., 98, 27L-31L (2006).
18. Woo, S. K., Kim, H. S., Kang, J. S., and Kwon, K. I., Bioequivalence and pharmacokinetics of carvedilol (25 mg) tablets in volunteers. Yakhak Hoeji, 45, 650-655 (2001).
19. Zarghi, A., Foroutan, S. M., Shafaati, A., and Khoddam, A. Quantification of carvedilol in human plasma by liquid chromatography using fluorescence detection: application in pharmacokinetic studies. J. Pharm. and Biomed. Anal., 44, 250-253 (2007).